Results 61 to 70 of about 2,541 (178)
Dietary Supplements Market Size Analysis in Iran From 2011 to 2015
Journal of Pharmacoeconomics and Pharmaceutical Management, 2019 Background: Dietary Supplement (DS) is a manufactured preparation intended to supplement the diet; unlike medications, they are not intended to diagnose, treat or cure disease.
Amirhossein Ghazizadeh Khosroshahi +5 more
doaj
Cost-Minimization of Availability of Fusidic Acid in the Treatment of Topical Infection in Iran
Journal of Pharmacoeconomics and Pharmaceutical Management, 2018 Background: Since at the time of this study fusidic acid was not available in the pharmaceutical market of Iran, this study was designed to investigate the economic aspects of the availability of fusidic acid for the treatment of topical infection in ...
Meysam Seyedifar +3 more
doaj
Pharmacoeconomics of Antibiotic Therapy
Canadian Journal of Infectious Diseases, 1994 During the past few years new drugs with greatly improved efficacy have become available to physicians and their patients. The higher purchase price of these new drugs is quite important and is quoted as a significant cause of the escalating cost of ...
Jacques Le Lorier
doaj +1 more source
Economic Burden of Paroxysmal Nocturnal Hemoglobinuria (PNH) and Secondary Problems Caused by PNH
Journal of Pharmacoeconomics and Pharmaceutical Management, 2022 Background: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired disorder of hematopoietic stem cells, in which red blood cells become susceptible to complement-mediated hemolysis.
Sina Dadfar +3 more
doaj
Pharmacoeconomic Analysis in Saudi Arabia: An Overdue Agenda Item for Action
Annals of Saudi Medicine, 2011 Pharmacoeconomics is a branch of health economics related to the most economical and efficient use of pharmaceuticals. Pharmacoeconomic research identifies, measures and compares the costs and outcomes (clinical, economic and humanistic) of ...
Al-Jazairi Abdulrazaq +2 more
doaj
An overview to pharmaceutical financing in Iran
Journal of Pharmacoeconomics and Pharmaceutical Management, 2017 Pharmaceutical expenditure is a substantial part of the health-care system budget. In Iran, people are paying about half of total pharmaceutical expenditure out of their pocket.
Mehdi Varmaghani +6 more
doaj
BMC Public Health, 2017 Background Hypertension affects one billion people globally and is one of the leading risk factors for cardiovascular and renal diseases. However, hypertension management remains poor, especially in rural China.
Yuting Zhang +4 more
doaj +1 more source
Journal of Pharmacoeconomics and Pharmaceutical Management, 2018 Background: Cinnovex is a biosimilar form of intramuscular (IM) interferon beta-1a (IFNβ-1a) manufactured in Iran for management of multiple sclerosis (MS). The present study aimed to determine the cost-utility of Cinnovex versus Avonex for patients with
Rahil Sadat Shahtaheri +2 more
doaj
Journal of Pharmacoeconomics and Pharmaceutical Management, 2017 Background: Equity is one of the pivotal aims and priorities of the pharmaceutical system. The World Health Organization report in 2000 clarifies the important role of equity in health-care systems. Equity and efficiency are prominent features of health-
Majid Davari +4 more
doaj